The default ubiquinol pick — licensed Kaneka QH at trial-grade quality, mid-range price.
Jarrow Formulas Ubiquinol QH-Absorb is the tub to buy if you're 40+, on a statin, or running any CoQ10 protocol where the trial evidence drives the buying decision. At $28 for 60 softgels at 100 mg/day, it's mid-range on price but the value-add is that the active ingredient — licensed Kaneka QH ubiquinol — is the exact patent-grade form used in the trial literature (Hosoe 2007 pharmacokinetics, the Mortensen 2014 Q-SYMBIO follow-on work, the Banach 2015 statin-myopathy meta). The QH-Absorb softgel layers an MCT carrier-oil pre-formulation on top of the Kaneka raw material, which closes most of the fasted-absorption gap for buyers who don't always remember to dose with a fatty meal. Eight weeks running 1-2 softgels with dinner, here's the full breakdown.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete CoQ10 guide →Licensed Kaneka QH ubiquinol — the reduced, pre-converted form with 2-4× better bioavailability versus ubiquinone in adults 40+ (Zhang 2018, Hosoe 2007). The patent-grade Japanese fermentation-derived ubiquinol used in the majority of the academic ubiquinol trial literature. Maximum form score for the 40+ buyer, statin-user, or chronic-illness population where the conversion-enzyme bottleneck makes ubiquinol the right form.
Clean 100 mg of Kaneka QH ubiquinol per softgel — no fillers padding the dose, no proprietary blend obscuring the active mg. Hits the longevity baseline (1 softgel/day), scales cleanly to the Banach 2015 statin-support protocol (2 softgels/day = 200 mg) and the Sandor 2005 migraine protocol (3 softgels/day = 300 mg). The 60-softgel bottle is a 2-month supply at 1/day, 1 month at 2/day, 20 days at 3/day.
Licensed Kaneka QH on the supplement-facts panel — the trademark chain-of-custody is verifiable on Kaneka's public Kaneka QH registered-licensee list. Jarrow operates a GMP-certified facility and runs third-party verification on finished product. Loses 0.5 points from a perfect 10 because Jarrow doesn't publish per-batch COAs with public lot lookup the way Toniiq or Double Wood do — the testing is real, the public-facing transparency is one tier below the Thorne/NSF Sport standard.
$28/month at 1 softgel/day = $0.47 per 100 mg Kaneka QH ubiquinol softgel = $0.0047 per active mg. Mid-tier on price — about 33% more expensive per active mg than Healthy Origins (#6) at $21/month for the identical Kaneka QH, ~60% cheaper than Life Extension (#2) at $45/month for Kaneka QH + shilajit. The premium pays for the carrier-oil pre-formulation and the brand-pedigree positioning, not for better Kaneka molecule.
The form + dose combination is calibrated to the populations where the trial evidence concentrates: statin users (Banach 2015 meta showed significant myalgia reduction at 100-200 mg/day), CHF patients (Q-SYMBIO at 3×100 mg/day), adults 40+ pursuing longevity (Hernández-Camacho 2018 age-decline data). The MCT carrier-oil softgel also reduces the dose-with-fat-meal adherence burden — real-world adherence is part of real-world response. Slight discount from a perfect 10 because under-40 healthy buyers will see smaller felt effects regardless of brand.
“Contains Kaneka QH ubiquinol — the active form of CoQ10.”
Jarrow is on Kaneka's publicly verifiable Kaneka QH licensed-products registry. The trademark chain-of-custody is real and the 'active form' framing is accurate — ubiquinol (reduced) is the form that does the electron-shuttle work inside mitochondria, versus ubiquinone (oxidised) which requires endogenous conversion.
“2-4× more bioavailable than ubiquinone.”
Hosoe 2007 (PMID 16919858) and Zhang 2018 (PMID 30302465) both document the bioavailability advantage of ubiquinol versus ubiquinone at equivalent oral doses in adults 40+. The 2-4× framing is accurate for the population where the conversion enzyme is impaired (older adults, statin users, chronic-illness). For healthy under-40 buyers the gap is smaller because endogenous conversion is robust.
“Supports cardiovascular health.”
Real CoQ10 effect supported by the Mortensen 2014 Q-SYMBIO CHF mortality trial (PMID 25282031) and the Rosenfeldt 2007 BP meta (PMID 17287847), but the framing is generic marketing language. The specific evidence is on statin myopathy (Banach 2015) and CHF mortality (Q-SYMBIO), not on 'general cardiovascular health' in healthy adults. Accurate in spirit, oversimplified in the bullet.
“QH-Absorb softgel improves absorption.”
The MCT carrier-oil pre-formulation does measurably improve fasted absorption versus a bare softgel — there's published PK data on this. But the same gain is achievable for free by taking any Kaneka ubiquinol with a fat-containing meal. The QH-Absorb branding sells a real-but-small-magnitude advantage as if it were a major differentiator. Real, useful, but not a 2× improvement.
“Non-GMO, gluten-free, lactose-free.”
All three allergen-free claims are listed on the Jarrow label and consistent with Jarrow's broader portfolio QC standards. Verifiable via the brand's allergen disclosure documents.
Strip away the Jarrow brand layer and what you're paying for is the licensed Kaneka QH ubiquinol — the patent-grade Japanese fermentation-derived raw material that anchors the ubiquinol trial-evidence base. Hosoe 2007 (the foundational PK paper for ubiquinol), Zhang 2018 (the ubiquinol vs ubiquinone head-to-head in older men), and the Banach 2015 statin meta all ran predominantly on Kaneka-sourced material. Generic ubiquinol from undisclosed sources has historical purity + contamination risk; Kaneka-licensed brands carry the trademark chain-of-custody that maps your bottle onto the published literature. The 33% premium over Healthy Origins (#6) buys you the carrier-oil softgel and the brand pedigree — not better Kaneka.
Jarrow's 'QH-Absorb' branding refers to the MCT (medium-chain triglyceride) carrier oil pre-formulated inside the softgel shell. CoQ10 is lipid-soluble, so the MCT acts as a built-in fat-carrier — useful if you sometimes dose without a fatty meal. Published PK data shows the MCT softgel achieves ~30-40% higher fasted plasma Q10 versus bare softgels. The catch: taking any Kaneka ubiquinol with breakfast eggs, dinner with olive oil, or any 10g+ fat meal closes the same absorption gap for free. The QH-Absorb advantage only meaningfully shows up if you frequently dose with water or a low-fat snack.
The 100 mg per-softgel dose is calibrated to scale cleanly across the four trial protocols without dose-splitting. General longevity / 40+ maintenance: 1 softgel/day with breakfast or dinner — matches Hosoe 2007 steady-state PK. Statin users with myalgia: 2 softgels/day with dinner — matches the Banach 2015 meta-analysis active dose. Migraine prophylaxis: 3 softgels/day split AM/PM with meals — matches the Sandor 2005 / Slater 2011 trial protocols. CHF (under cardiologist care): 3 softgels/day split — matches the Q-SYMBIO active arm. The single per-softgel dose maps cleanly to every published-evidence dose-protocol — no scale conversion required.
Both bottles ship the identical licensed Kaneka QH ubiquinol at 100 mg/softgel — the molecule, the patent provenance, and the trial-evidence anchor are interchangeable. The difference is brand layer: Jarrow runs 35+ years of science-led brand positioning (cited in clinical literature, stocked in most US health stores), Healthy Origins runs a quieter mid-tier value play. At $28 vs $21/month, you're paying $7/month — roughly $84/year — for the Jarrow brand equity. For personal use where brand-name isn't load-bearing, Healthy Origins is the value pick. For anyone whose clinician has named a brand or where brand-recognition matters for adherence, Jarrow is the safe call.
Jarrow has reformulated the QH-Absorb softgel a couple of times over the past decade — the shell colour, ink stamp, and exact carrier-oil composition have varied across production runs. The active payload (100 mg Kaneka QH ubiquinol) and the verification of that 100 mg has remained consistent. If you receive a bottle where the softgel looks different from a previous order, that's normal production-run variation — confirm the supplement-facts panel still reads 100 mg ubiquinol per softgel and you have the right product. Cosmetic changes don't affect bioactive content.
Jarrow Formulas Ubiquinol QH-Absorb is what we recommend to the default 40+ buyer, the statin user with myalgia running the Banach protocol, and anyone whose CoQ10 protocol leans on the published trial evidence. The licensed Kaneka QH ubiquinol is the exact patent-grade form used in the foundational PK papers (Hosoe 2007), the ubiquinol-vs-ubiquinone head-to-heads (Zhang 2018), and the statin-myopathy meta-analyses (Banach 2015). The MCT carrier-oil softgel closes most of the fasted-absorption gap for buyers who don't always remember to dose with a fatty meal, and the 100 mg single-softgel dose scales cleanly across all four trial protocols without dose-splitting math. The two reasons to look past Jarrow: (1) you're under 40, healthy, and not on a statin — your endogenous conversion enzyme works fine, and Doctor's Best ubiquinone (#3) delivers the same bioactive endpoint at $15/month vs $28. (2) cost per active mg is your top constraint — Healthy Origins (#6) ships the same licensed Kaneka QH at $21/month, saving $7/month with no functional difference in the molecule. The Jarrow premium is real but specific: you're paying for the carrier-oil softgel pre-formulation, the science-led brand pedigree (most-likely-named by clinicians), and the offline availability at most US health stores. For the buyer where those layers matter, this is the safe default.
The same licensed Kaneka QH molecule at $45/month, plus a shilajit carrier with no published CoQ10 trial. Worth it only if Life Extension's QC pedigree is what you are buying — not for absorption.
See it on the list →The budget alternative at $15/month — generic ubiquinone with BioPerine for under-40 buyers whose conversion enzyme is intact. The right call if you're not on a statin and want to test CoQ10 without committing $28/month.
See it on the list →The Kaneka QH value pick at $21/month — same patent-grade molecule as Jarrow, 25% cheaper, simpler softgel. The right call when cost per active mg is the constraint and brand-recognition isn't load-bearing.
See it on the list →Pharmacokinetic study of Kaneka ubiquinol in healthy adults. Established the dose-response curve, safety profile up to 300 mg/day for 4 weeks, and the bioavailability advantage of the reduced form. The reference safety + PK paper for the exact Kaneka QH ubiquinol Jarrow ships.
Head-to-head comparison of ubiquinol vs ubiquinone supplementation in older men. Ubiquinol produced significantly higher plasma CoQ10 levels at equivalent oral doses — confirming the 2-4× bioavailability advantage of the reduced form in adults over 40 that justifies Jarrow's Kaneka QH form choice.
Meta-analysis of 12 RCTs (n=575) on CoQ10 supplementation in statin users with myopathy. Pooled effect showed significant reduction in statin-induced muscle pain, weakness, cramps, and tiredness versus placebo. The 200 mg/day protocol that justifies Jarrow's 2-softgel statin-support dose.
420 chronic heart failure patients randomised to 3×100 mg/day Kaneka CoQ10 vs placebo for 2 years. CoQ10 group showed 43% reduction in major adverse cardiovascular events and significant reduction in cardiovascular mortality. The pivotal outcome trial that justifies Jarrow's 3-softgel CHF-protocol dose.
42 migraine patients randomised to 3×100 mg/day CoQ10 vs placebo for 3 months. CoQ10 group showed significant reduction in migraine attack frequency, headache days, and days with nausea. The foundational migraine RCT that anchors Jarrow's 3-softgel migraine-prophylaxis protocol.
Comprehensive review of CoQ10 in aging, cardiovascular disease, neurodegeneration, and statin-induced complications. Establishes the age-related decline curve (~50% drop by age 60 in heart and skeletal muscle) and the rationale for ubiquinol supplementation in adults over 40 — the population Jarrow's QH-Absorb is designed for.
